small molecule

FILSPARI

SPARSENTAN

Loss of exclusivitySeptember 2031FDA regulatory exclusivity expiry

CompanyTravere Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand name	FILSPARI
Active ingredient	SPARSENTAN
Strength	200MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
9993461	March 2030	use U-4495
9662312	March 2030	use U-4495

Regulatory exclusivity

Code	Expires
ODE-493	September 2031
ODE-389	February 2030
I-989	April 2029
NCE	February 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Travere Therapeutics